Search

Your search keyword '"Levine, Arie"' showing total 621 results
Start Over Author "Levine, Arie"
621 results on '"Levine, Arie"'

1. STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN

Author

Pujol-Muncunill, Gemma, Navas-López, Víctor Manuel, Ledder, Oren, Cohen, Shlomi, Lekar, Marina, Turner, Dan, Kolho, Kaija-Leena, Levine, Arie, Croft, Nicholas M., Bronsky, Jiri, Shouval, Dror S., Assa, Amit, Harris, Rachel, Kiparissi, Fevronia, Aloi, Marina, Afzal, Nadeem Ahmad, Tzivinikos, Christos, Barrio, Josefa, Norden, Christoph, Vega, Maria Jesús Balboa, Buderus, Stephan, de Valderrama, Ana Fernández, de Ridder, Lissy, García-Romero, Ruth, Medina, Enrique, Sánchez, César, Velasco, Marta, Vicente, Saioa, Wilson, David C., Naik, Sandhia, Hradsky, Ondrej, Cococcioni, Lucia, and Martin-de-Carpi, Javier

Published
2024
Full Text
View/download PDF

2. Unfermented β-fructan Fibers Fuel Inflammation in Select Inflammatory Bowel Disease Patients

Author

Armstrong, Heather K., Bording-Jorgensen, Michael, Santer, Deanna M., Zhang, Zhengxiao, Valcheva, Rosica, Rieger, Aja M., Sung-Ho Kim, Justin, Dijk, Stephanie I., Mahmood, Ramsha, Ogungbola, Olamide, Jovel, Juan, Moreau, France, Gorman, Hayley, Dickner, Robyn, Jerasi, Jeremy, Mander, Inderdeep K., Lafleur, Dawson, Cheng, Christopher, Petrova, Alexandra, Jeanson, Terri-Lyn, Mason, Andrew, Sergi, Consolato M., Levine, Arie, Chadee, Kris, Armstrong, David, Rauscher, Sarah, Bernstein, Charles N., Carroll, Matthew W., Huynh, Hien Q., Walter, Jens, Madsen, Karen L., Dieleman, Levinus A., and Wine, Eytan

Published
2023
Full Text
View/download PDF

3. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

Author

Caron, Bénédicte, Abreu, Maria T., Siegel, Corey A., Panaccione, Remo, Sands, Bruce E., Dignass, Axel, Turner, Dan, Dotan, Iris, Hart, Ailsa L., Ahuja, Vineet, Allez, Matthieu, Ananthakrishnan, Ashwin N., Ghosh, Subrata, Griffiths, Anne M., Halfvarson, Jonas, Kaser, Arthur, Kotze, Paulo G., Koutroubakis, Ioannis E., Lakatos, Peter L., Levine, Arie, Lewis, James D., Magro, Fernando, Mantzaris, Gerassimos J., O’Morain, Colm, Ran, Zhihua, Reinisch, Walter, Rogler, Gerhard, Sachar, David B., Siegmund, Britta, Silverberg, Mark S., Sood, Ajit, Spinelli, Antonino, Steinwurz, Flavio, Tysk, Curt, Yamamoto-Furusho, Jesus K., Schreiber, Stefan, Rubin, David T., Sandborn, William J., Danese, Silvio, and Peyrin-Biroulet, Laurent

Published
2022
Full Text
View/download PDF

4. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial

Author

Yanai, Henit, Levine, Arie, Hirsch, Ayal, Boneh, Rotem Sigall, Kopylov, Uri, Eran, Hagar Banai, Cohen, Nathaniel A, Ron, Yulia, Goren, Idan, Leibovitzh, Haim, Wardi, Joram, Zittan, Eran, Ziv-Baran, Tomer, Abramas, Lee, Fliss-Isakov, Naomi, Raykhel, Barbara, Gik, Tamar Pfeffer, Dotan, Iris, and Maharshak, Nitsan

Published
2022
Full Text
View/download PDF

7. Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases

Author

Levine, Arie, Rhodes, Jonathan M., Lindsay, James O., Abreu, Maria T., Kamm, Michael A., Gibson, Peter R., Gasche, Christoph, Silverberg, Mark S., Mahadevan, Uma, Boneh, Rotem Sigall, Wine, Eyton, Damas, Oriana M., Syme, Graeme, Trakman, Gina L., Yao, Chu Kion, Stockhamer, Stefanie, Hammami, Muhammad B., Garces, Luis C., Rogler, Gerhard, Koutroubakis, Ioannis E., Ananthakrishnan, Ashwin N., McKeever, Liam, and Lewis, James D.

Published
2020
Full Text
View/download PDF

11. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Author

Anderson, Carl A, Boucher, Gabrielle, Lees, Charlie W, Franke, Andre, D'Amato, Mauro, Taylor, Kent D, Lee, James C, Goyette, Philippe, Imielinski, Marcin, Latiano, Anna, Lagacé, Caroline, Scott, Regan, Amininejad, Leila, Bumpstead, Suzannah, Baidoo, Leonard, Baldassano, Robert N, Barclay, Murray, Bayless, Theodore M, Brand, Stephan, Büning, Carsten, Colombel, Jean-Frédéric, Denson, Lee A, De Vos, Martine, Dubinsky, Marla, Edwards, Cathryn, Ellinghaus, David, Fehrmann, Rudolf SN, Floyd, James AB, Florin, Timothy, Franchimont, Denis, Franke, Lude, Georges, Michel, Glas, Jürgen, Glazer, Nicole L, Guthery, Stephen L, Haritunians, Talin, Hayward, Nicholas K, Hugot, Jean-Pierre, Jobin, Gilles, Laukens, Debby, Lawrance, Ian, Lémann, Marc, Levine, Arie, Libioulle, Cecile, Louis, Edouard, McGovern, Dermot P, Milla, Monica, Montgomery, Grant W, Morley, Katherine I, Mowat, Craig, Ng, Aylwin, Newman, William, Ophoff, Roel A, Papi, Laura, Palmieri, Orazio, Peyrin-Biroulet, Laurent, Panés, Julián, Phillips, Anne, Prescott, Natalie J, Proctor, Deborah D, Roberts, Rebecca, Russell, Richard, Rutgeerts, Paul, Sanderson, Jeremy, Sans, Miquel, Schumm, Philip, Seibold, Frank, Sharma, Yashoda, Simms, Lisa A, Seielstad, Mark, Steinhart, A Hillary, Targan, Stephan R, van den Berg, Leonard H, Vatn, Morten, Verspaget, Hein, Walters, Thomas, Wijmenga, Cisca, Wilson, David C, Westra, Harm-Jan, Xavier, Ramnik J, Zhao, Zhen Z, Ponsioen, Cyriel Y, Andersen, Vibeke, Torkvist, Leif, Gazouli, Maria, Anagnou, Nicholas P, Karlsen, Tom H, Kupcinskas, Limas, Sventoraityte, Jurgita, Mansfield, John C, Kugathasan, Subra, Silverberg, Mark S, Halfvarson, Jonas, Rotter, Jerome I, Mathew, Christopher G, Griffiths, Anne M, Gearry, Richard, Ahmad, Tariq, Brant, Steven R, and Chamaillard, Mathias

Subjects
Biological Sciences, Genetics, Autoimmune Disease, Human Genome, Crohn's Disease, Digestive Diseases, Nutrition, Inflammatory Bowel Disease, Prevention, Oral and gastrointestinal, Colitis, Ulcerative, Crohn Disease, Genome-Wide Association Study, Humans, Risk, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association study datasets, comprising 6,687 cases and 19,718 controls, and followed up the top association signals in 9,628 cases and 12,917 controls. We identified 29 additional risk loci (P < 5 × 10(-8)), increasing the number of ulcerative colitis-associated loci to 47. After annotating associated regions using GRAIL, expression quantitative trait loci data and correlations with non-synonymous SNPs, we identified many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1. The total number of confirmed inflammatory bowel disease risk loci is now 99, including a minimum of 28 shared association signals between Crohn's disease and ulcerative colitis.

Published
2011

15. Metabolome Changes With Diet-Induced Remission in Pediatric Crohn’s Disease

Author

Ghiboub, Mohammed, primary, Penny, Susanne, additional, Verburgt, Charlotte M., additional, Boneh, Rotem Sigall, additional, Wine, Eytan, additional, Cohen, Alejandro, additional, Dunn, Katherine A., additional, Pinto, Devanand M., additional, Benninga, Marc A., additional, de Jonge, Wouter J., additional, Levine, Arie, additional, and Van Limbergen, Johan E., additional

Published
2022
Full Text
View/download PDF

16. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN

Author

Yerushalmy-Feler, Anat, primary, Pujol-Muncunill, Gemma, additional, Martin-de-Carpi, Javier, additional, Kolho, Kaija-Leena, additional, Levine, Arie, additional, Olbjørn, Christine, additional, Granot, Maya, additional, Bramuzzo, Matteo, additional, Rolandsdotter, Helena, additional, Mouratidou, Natalia, additional, Hradsky, Ondrej, additional, Scarallo, Luca, additional, Matar, Manar, additional, Rimon, Ramit Magen, additional, Rinawi, Firas, additional, Shalem, Tzippi, additional, Najajra, Hisham, additional, de Meij, Tim, additional, Aloi, Marina, additional, Rodríguez-Belvís, Marta Velasco, additional, Alvisi, Patrizia, additional, Schneider, Anna-Maria, additional, van Rheenen, Patrick, additional, Navas-López, Víctor Manuel, additional, Kiparissi, Fevronia, additional, Barrio, Josefa, additional, Turner, Dan, additional, and Cohen, Shlomi, additional

Published
2022
Full Text
View/download PDF

22. High Impact of Pediatric Inflammatory Bowel Disease on Caregivers’ Work Productivity and Daily Activities:An International Prospective Study

Author

Klomberg, Renz C.W., Aardoom, Martine A., Kemos, Polychronis, Rizopoulos, Dimitris, Ruemmele, Frank M., Croft, Nicholas M., de Ridder, Lissy, Neyt, Mattias, Turner, Dan, Focht, Gili, Samsom, Janneke, Veereman, Gigi, Koletzko, Sibylle, Brückner, Annecarin, Levine, Arie, Russell, Richard, Griffiths, Anne, Aloi, Marina, Walters, Thomas, Walker, Michael, Klomberg, Renz C.W., Aardoom, Martine A., Kemos, Polychronis, Rizopoulos, Dimitris, Ruemmele, Frank M., Croft, Nicholas M., de Ridder, Lissy, Neyt, Mattias, Turner, Dan, Focht, Gili, Samsom, Janneke, Veereman, Gigi, Koletzko, Sibylle, Brückner, Annecarin, Levine, Arie, Russell, Richard, Griffiths, Anne, Aloi, Marina, Walters, Thomas, and Walker, Michael

Abstract

Objectives: To evaluate the longitudinal evolution of work productivity loss and activity impairment in caregivers of children with inflammatory bowel disease (IBD). We also evaluated the associations between these impairments, IBD-related factors, and caregivers’ health-related quality of life (HRQOL) and estimated the indirect costs related to work absenteeism. Study design: Since January 2017, children with newly diagnosed IBD were enrolled prospectively in the Pediatric Inflammatory Bowel Disease Network for Safety, Efficacy, Treatment and Quality improvement of care study. The impact of pediatric-onset IBD on caregivers' socioeconomic functioning (work and daily activities) and HRQOL was assessed using the Work Productivity and Activity Impairment for caregivers questionnaire and the European Quality of Life Five Dimension Five Level questionnaire, at diagnosis and 3 and 12 months of age. Generalized estimating equation models were applied to evaluate outcomes longitudinally, adjusted for IBD type, disease activity, and child's age at diagnosis. Results: Up to July 2021, 491 children with IBD were eligible for analysis of caregivers' Work Productivity and Activity Impairment questionnaire. At diagnosis, the mean caregivers' employment rate was 78.4%; the adjusted mean work productivity loss was 44.6% (95% CI, 40.2%-49.0%), and the adjusted mean activity impairment was 34.3% (95% CI, 30.8%-37.7%). Work productivity loss and activity impairment significantly decreased over time and were associated with disease activity, but not with IBD type or child's age. Caregivers' HRQOL was associated with both impairments. Costs related to work absenteeism were at least €6272 ($7276) per patient during the first year after diagnosis. Conclusions: Caregivers of children with IBD experience significant impairments in work and daily activities, especially at diagnosis. The impact decreases thereafter and is associated with disease activity and caregivers’ HRQOL. Work absent

Published
2022

23. The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease:A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry

Author

Aardoom, Martine A., Klomberg, Renz C.W., Kemos, Polychronis, Ruemmele, Frank M., Fagbemi, Andrew, Kiparissi, Fevronia, Schweizer, Joachim J., Sebastian, Shaji, Russell, Richard, Torrente, Franco, Van Mill, Marije, De Ridder, Lissy, Croft, Nicholas, Tempia-Caliera, Michela, Lee, Way Seah, Pigott, Anna J., Classen, Martin, Morris, Mary Anne, Muhammed, Rafeeq, Hussey, Seamus, Cananzi, Mara, Menz, Timothy J., Wahbeh, Ghassan T., Van Ommen, C. H.Heleen, Turner, Dan, Focht, Gili, Samsom, Janneke, Veereman, Gigi, Neyt, Mattias, Koletzko, Sibylle, Brückner, Annecarin, Levine, Arie, Weiner, Dror, Griffiths, Anne, Aloi, Marina, Raes, Jeroen, Christiaens, Annick, Walters, Thomas, Walker, Michael, Ruemelle, Frank, Demange, Christine Nguyen, Bigot, Laetitia, Aardoom, Martine A., Klomberg, Renz C.W., Kemos, Polychronis, Ruemmele, Frank M., Fagbemi, Andrew, Kiparissi, Fevronia, Schweizer, Joachim J., Sebastian, Shaji, Russell, Richard, Torrente, Franco, Van Mill, Marije, De Ridder, Lissy, Croft, Nicholas, Tempia-Caliera, Michela, Lee, Way Seah, Pigott, Anna J., Classen, Martin, Morris, Mary Anne, Muhammed, Rafeeq, Hussey, Seamus, Cananzi, Mara, Menz, Timothy J., Wahbeh, Ghassan T., Van Ommen, C. H.Heleen, Turner, Dan, Focht, Gili, Samsom, Janneke, Veereman, Gigi, Neyt, Mattias, Koletzko, Sibylle, Brückner, Annecarin, Levine, Arie, Weiner, Dror, Griffiths, Anne, Aloi, Marina, Raes, Jeroen, Christiaens, Annick, Walters, Thomas, Walker, Michael, Ruemelle, Frank, Demange, Christine Nguyen, and Bigot, Laetitia

Abstract

Background and Aims: Guidelines regarding thromboprophylaxis for venous thromboembolisms [VTEs] in children with inflammatory bowel disease [IBD] are based on limited paediatric evidence. We aimed to prospectively assess the incidence of VTEs in paediatric-onset IBD [PIBD], characterize PIBD patients with a VTE and identify potential IBD-related risk factors. Methods: From October 2016 to September 2020, paediatric gastroenterologists prospectively replied to the international Safety Registry, monthly indicating whether they had observed a VTE case in a patient <19 years with IBD. IBD details [type, Paris classification, clinical and biochemical disease activity, treatment] and VTE details [type, location, treatment, outcome] were collected. To estimate VTE incidence, participants annually reported the number of PIBD patients, data source and catchment area of their centre. A systematic literature review and meta-analysis was performed to calculate the VTE incidence in the general paediatric population. Results: Participation of 129 PIBD centres resulted in coverage of 24 802 PIBD patients. Twenty cases of VTE were identified [30% Crohn's disease]. The incidence of VTEs was 3.72 (95% confidence interval [CI] 2.27-5.74) per 10 000 person-years, 14-fold higher than in the general paediatric population (0.27 [95% CI 0.18-0.38], p < 0.001). Cerebral sinus venous thrombosis was most frequently reported [50%]. All but one patient had active IBD, 45% were using steroids and 45% were hospitalized. No patient received thromboprophylaxis, whereas according to current PIBD guidelines, this was recommended in 4/20 patients. Conclusion: There is an increased risk of VTEs in the PIBD population compared to the general paediatric population. Awareness of VTE occurrence and prevention should be extended to all PIBD patients with active disease, especially those hospitalized.

Published
2022

24. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN

Author

Ledder, Oren, Assa, Amit, Levine, Arie, Escher, Johanna C, de Ridder, Lissy, Ruemmele, Frank, Shah, Neil, Shaoul, Ron, Wolters, Victorien M, Rodrigues, Astor, Uhlig, Holm H, Posovsky, Carsten, Kolho, Kaija-Leena, Jakobsen, Christian, Cohen, Shlomi, Shouval, Dror S, de Meij, Tim, Martin-de-Carpi, Javier, Richmond, Lisa, Bronsky, Jiri, Friedman, Mira, and Turner, Dan

Published
2017
Full Text
View/download PDF

28. High impact of pediatric inflammatory bowel disease on caregivers’ work productivity and daily activities: an international prospective study

Author

Klomberg, Renz C.W., primary, Aardoom, Martine A., additional, Kemos, Polychronis, additional, Rizopoulos, Dimitris, additional, Ruemmele, Frank M., additional, Croft, Nicholas M., additional, de Ridder, Lissy, additional, Neyt, Mattias, additional, Turner, Dan, additional, Focht, Gili, additional, Croft, Nicholas, additional, Samsom, Janneke, additional, Veereman, Gigi, additional, Klomberg, Renz, additional, Koletzko, Sibylle, additional, Brückner, Annecarin, additional, Levine, Arie, additional, Russell, Richard, additional, Griffiths, Anne, additional, Aloi, Marina, additional, Walters, Thomas, additional, Walker, Michael, additional, and Ruemelle, Frank, additional

Published
2022
Full Text
View/download PDF

30. The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry

Author

Aardoom, Martine A., Klomberg, Renz C.W., Kemos, Polychronis, Ruemmele, Frank M., Fagbemi, Andrew, Kiparissi, Fevronia, Schweizer, Joachim J., Sebastian, Shaji, Russell, Richard, Torrente, Franco, Van Mill, Marije, De Ridder, Lissy, Croft, Nicholas, Tempia-Caliera, Michela, Lee, Way Seah, Pigott, Anna J., Classen, Martin, Morris, Mary Anne, Muhammed, Rafeeq, Hussey, Seamus, Cananzi, Mara, Menz, Timothy J., Wahbeh, Ghassan T., Van Ommen, C. H.Heleen, Turner, Dan, Focht, Gili, Samsom, Janneke, Veereman, Gigi, Neyt, Mattias, Koletzko, Sibylle, Brückner, Annecarin, Levine, Arie, Weiner, Dror, Griffiths, Anne, Aloi, Marina, Raes, Jeroen, Christiaens, Annick, Walters, Thomas, Walker, Michael, Ruemelle, Frank, Demange, Christine Nguyen, Bigot, Laetitia, and Pediatrics

Subjects
Pediatrics, medicine.medical_specialty, Population, Disease, Inflammatory bowel disease, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Prospective Studies, Registries, education, Child, Venous Thrombosis, education.field_of_study, Crohn's disease, business.industry, Incidence (epidemiology), Incidence, Gastroenterology, Anticoagulants, General Medicine, Venous Thromboembolism, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, 3. Good health, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Complication, business, Cohort study
Abstract

Background and Aims Guidelines regarding thromboprophylaxis for venous thromboembolisms [VTEs] in children with inflammatory bowel disease [IBD] are based on limited paediatric evidence. We aimed to prospectively assess the incidence of VTEs in paediatric-onset IBD [PIBD], characterize PIBD patients with a VTE and identify potential IBD-related risk factors. Methods From October 2016 to September 2020, paediatric gastroenterologists prospectively replied to the international Safety Registry, monthly indicating whether they had observed a VTE case in a patient Results Participation of 129 PIBD centres resulted in coverage of 24 802 PIBD patients. Twenty cases of VTE were identified [30% Crohn’s disease]. The incidence of VTEs was 3.72 (95% confidence interval [CI] 2.27–5.74) per 10 000 person-years, 14-fold higher than in the general paediatric population (0.27 [95% CI 0.18–0.38], p < 0.001). Cerebral sinus venous thrombosis was most frequently reported [50%]. All but one patient had active IBD, 45% were using steroids and 45% were hospitalized. No patient received thromboprophylaxis, whereas according to current PIBD guidelines, this was recommended in 4/20 patients. Conclusion There is an increased risk of VTEs in the PIBD population compared to the general paediatric population. Awareness of VTE occurrence and prevention should be extended to all PIBD patients with active disease, especially those hospitalized.

Published
2021

35. Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial

Author

Sarbagili Shabat, Chen, primary, Scaldaferri, Franco, additional, Zittan, Eran, additional, Hirsch, Ayal, additional, Mentella, Maria Chiara, additional, Musca, Tania, additional, Cohen, Nathaniel Aviv, additional, Ron, Yulia, additional, Fliss Isakov, Naomi, additional, Pfeffer, Jorge, additional, Yaakov, Michal, additional, Fanali, Caterina, additional, Turchini, Laura, additional, Masucci, Luca, additional, Quaranta, Gianluca, additional, Kolonimos, Nitzan, additional, Godneva, Anastasia, additional, Weinberger, Adina, additional, Kopylov, Uri, additional, Levine, Arie, additional, and Maharshak, Nitsan, additional

Published
2021
Full Text
View/download PDF

39. Reply

Author

Lewis, James D., primary and Levine, Arie, additional

Published
2021
Full Text
View/download PDF

40. The Medical Management of Paediatric Crohn's Disease:An ECCO-ESPGHAN Guideline Update

Author

Van Rheenen, Patrick F., Aloi, Marina, Assa, Amit, Bronsky, Jiri, Escher, Johanna C., Fagerberg, Ulrika L., Gasparetto, Marco, Gerasimidis, Konstantinos, Griffiths, Anne, Henderson, Paul, Koletzko, Sibylle, Kolho, Kaija Leena, Levine, Arie, Van Limbergen, Johan, Martin De Carpi, Francisco Javier, Navas-López, Víctor Manuel, Oliva, Salvatore, De Ridder, Lissy, Russell, Richard K., Shouval, Dror, Spinelli, Antonino, Turner, Dan, Wilson, David, Wine, Eytan, Ruemmele, Frank M., Van Rheenen, Patrick F., Aloi, Marina, Assa, Amit, Bronsky, Jiri, Escher, Johanna C., Fagerberg, Ulrika L., Gasparetto, Marco, Gerasimidis, Konstantinos, Griffiths, Anne, Henderson, Paul, Koletzko, Sibylle, Kolho, Kaija Leena, Levine, Arie, Van Limbergen, Johan, Martin De Carpi, Francisco Javier, Navas-López, Víctor Manuel, Oliva, Salvatore, De Ridder, Lissy, Russell, Richard K., Shouval, Dror, Spinelli, Antonino, Turner, Dan, Wilson, David, Wine, Eytan, and Ruemmele, Frank M.

Abstract

Objective: We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn's disease [CD]. Methods: We formed 10 working groups and formulated 17 PICO-structured clinical questions [Patients, Intervention, Comparator, and Outcome]. A systematic literature search from January 1, 1991 to March 19, 2019 was conducted by a medical librarian using MEDLINE, EMBASE, and Cochrane Central databases. A shortlist of 30 provisional statements were further refined during a consensus meeting in Barcelona in October 2019 and subjected to a vote. In total 22 statements reached ≥80% agreement and were retained. Results: We established that it was key to identify patients at high risk of a complicated disease course at the earliest opportunity, to reduce bowel damage. Patients with perianal disease, stricturing or penetrating behaviour, or severe growth retardation should be considered for up-front anti-tumour necrosis factor [TNF] agents in combination with an immunomodulator. Therapeutic drug monitoring to guide treatment changes is recommended over empirically escalating anti-TNF dose or switching therapies. Patients with low-risk luminal CD should be induced with exclusive enteral nutrition [EEN], or with corticosteroids when EEN is not an option, and require immunomodulator-based maintenance therapy. Favourable outcomes rely on close monitoring of treatment response, with timely adjustments in therapy when treatment targets are not met. Serial faecal calprotectin measurements or small bowel imaging [ultrasound or magnetic resonance enterography] are more reliable markers of treatment response than clinical scores alone. Conclusions: We present state-of-the-art guidance on the medical treatment and long-term management of children and adolescents with CD.

Published
2021

44. Su522 CHARACTERIZATION OF THE EFFECT OF NUTRITIONAL THERAPIES ON GUT METABOLITES COMPOSITION IN PROSPECTIVE CLINICAL TRIAL OF PEDIATRIC CROHN'S DISEASE PATIENTS

Author

Ghiboub, Mohammed, primary, Penny, Susanne, additional, Verburgt, Charlotte M., additional, Boneh, Rotem S., additional, Wine, Eytan, additional, Cohen, Alejandro, additional, Dunn, Katherine A., additional, Devanand, Pinto, additional, Benninga, Marc A., additional, De Jonge, Wouter J., additional, Levine, Arie, additional, and van Limbergen, Johan, additional

Published
2021
Full Text
View/download PDF

46. The Effect of Nutritional Therapy on Bone Mineral Density and Bone Metabolism in Pediatric Crohn Disease

Author

Lev-Tzion, Raffi, primary, Ben-Moshe, Tehila, additional, Abitbol, Guila, additional, Ledder, Oren, additional, Peleg, Sarit, additional, Millman, Peri, additional, Shaoul, Ron, additional, Kori, Michal, additional, Assa, Amit, additional, Cohen, Shlomi, additional, Strich, David, additional, Revel-Vilk, Shoshana, additional, Tiomkin, Maayan, additional, Levine, Arie, additional, Sigall Boneh, Rotem, additional, and Turner, Dan, additional

Published
2021
Full Text
View/download PDF

49. Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment

Author

Neyt, Mattias, primary, Christiaens, Annick, additional, Aloi, Marina, additional, de Ridder, Lissy, additional, Croft, Nicholas M, additional, Koletzko, Sibylle, additional, Levine, Arie, additional, Turner, Dan, additional, Russell, Richard K, additional, Ruemmele, Frank M, additional, and Veereman, Gigi, additional

Published
2021
Full Text
View/download PDF

50. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype, and disease severity

Author

Wine, Eytan, Reif, Shimon S., Leshinsky-Silver, Esther, Weiss, Batya, Shaoul, Ron R., Shamir, Raanan, Wasserman, Dror, Lerner, Aaron, Boaz, Mona, and Levine, Arie

Subjects
Phenotype -- Influence, Genotype -- Influence, Dwarfism -- Diagnosis, Dwarfism -- Genetic aspects, Crohn's disease -- Diagnosis, Crohn's disease -- Risk factors, Crohn's disease -- Care and treatment, Crohn's disease -- Development and progression
Abstract

Background. Delayed growth is a well-established feature of pediatric Crohn&apos;s disease. Several factors have been shown to affect growth, including disease location, severity, and treatment. The recently discovered NOD2 gene has been correlated to ileal location of Crohn&apos;s disease and subsequently could affect growth through the resulting phenotype or as an independent risk factor. The aim of our study was to determine if growth retardation is affected by genotype independently of disease location or severity. Methods. Genotyping for 3 NOD2 single-nucleotide polymorphisms was performed in 93 patients with detailed growth records. Parameters including disease location, disease severity, and NOD 2 genotype and their effect on z scores for height and weight at disease onset and during follow-up were analyzed. Results. NOD2 mutations were correlated with ileal location but not with disease severity or growth retardation. Ileal involvement was significantly associated with height retardation at disease onset and the lowest z score during follow-up. Use of steroids affected weight but not height. Regression models for growth variables revealed that the strongest association with impaired growth is with disease severity (weight- and height-failure odds ratios: 6.17 and 4.52, respectively). Conclusions. Severity of disease is correlated with growth failure for both height and weight. Location of disease is a weaker predictor of disordered growth and is correlated with growth retardation but not growth failure. The NOD2 genotype was not correlated with growth retardation or growth failure. Pediatrics 2004;114:1281-1286; NOD2, height failure, weight failure, Crohn&apos;s disease, growth, inflammatory bowel disease, genes, pediatric., ABBREVIATIONS. CD, Crohn's disease; SNP, single-nucleotide polymorphism; PCR, polymerase chain reaction; OR, odds ratio; CI, 95% confidence interval Growth retardation is a frequent feature of pediatric Crohn's disease (CD). Up [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results